---
figid: PMC7434989__cs-134-cs20191211-g2
figlink: pmc/articles/PMC7434989/figure/F2/
number: Figure 2
caption: (A) Schematic representation of the stepwise binding process for the IL-6
  family members, with IL-6 as an example. The site 1 interaction involves cytokine
  binding to the respective receptor, with the site 2 interaction generally between
  the cytokine and the common gp130 receptor chain, finally site 3 interactions involve
  formation of the final active signalling complex, in this case, formation of the
  IL-6/IL-6R/gp130 hexameric complex. (B) General outline of the IL-6 family cytokine
  signalling pathway. Formation of an active hexameric complex leads to activation
  of JAKs with subsequent activation of the STAT3, MAPK, and PI3K pathways (left).
  This results in up-regulation of the negative regulator SOCS3, as well as a range
  of inflammatory and pro-tumorigenic molecules. The pathway is inhibited by SOCS3,
  PIAS3, and PTPs via dephosphorylation, ubiquitin-mediated proteasomal degradation,
  and SUMOylation (right).
pmcid: PMC7434989
papertitle: Emerging roles for the IL-6 family of cytokines in pancreatic cancer.
reftext: Gemma van Duijneveldt, et al. Clin Sci (Lond). 2020 Aug;134(16):2091-2115.
pmc_ranked_result_index: '5850'
pathway_score: 0.6456485
filename: cs-134-cs20191211-g2.jpg
figtitle: Emerging roles for the IL-6 family of cytokines in pancreatic cancer
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7434989__cs-134-cs20191211-g2.html
  '@type': Dataset
  description: (A) Schematic representation of the stepwise binding process for the
    IL-6 family members, with IL-6 as an example. The site 1 interaction involves
    cytokine binding to the respective receptor, with the site 2 interaction generally
    between the cytokine and the common gp130 receptor chain, finally site 3 interactions
    involve formation of the final active signalling complex, in this case, formation
    of the IL-6/IL-6R/gp130 hexameric complex. (B) General outline of the IL-6 family
    cytokine signalling pathway. Formation of an active hexameric complex leads to
    activation of JAKs with subsequent activation of the STAT3, MAPK, and PI3K pathways
    (left). This results in up-regulation of the negative regulator SOCS3, as well
    as a range of inflammatory and pro-tumorigenic molecules. The pathway is inhibited
    by SOCS3, PIAS3, and PTPs via dephosphorylation, ubiquitin-mediated proteasomal
    degradation, and SUMOylation (right).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GAB1
  - GRB2
  - PTPN11
  - SOCS3
  - JAK1
  - SOS1
  - SOS2
  - HRAS
  - KRAS
  - NRAS
  - PTS
  - AKT2
  - AKT3
  - AKT1
  - STAT3
  - ARAF
  - BRAF
  - RAF1
  - PIAS3
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - JAK2
  - IL6R
  - O
genes:
- word: Gab1
  symbol: GAB1
  source: hgnc_symbol
  hgnc_symbol: GAB1
  entrez: '2549'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: SHP2
  symbol: SHP2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: SHP2
  symbol: SHP2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: socs3
  symbol: SOCS3
  source: hgnc_symbol
  hgnc_symbol: SOCS3
  entrez: '9021'
- word: JAK1
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK1
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PTPS
  symbol: PTPS
  source: hgnc_alias_symbol
  hgnc_symbol: PTS
  entrez: '5805'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PIAS3
  symbol: PIAS3
  source: hgnc_symbol
  hgnc_symbol: PIAS3
  entrez: '10401'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
chemicals:
- word: O
  source: MESH
  identifier: D013481
diseases: []
---
